5AR1 Stock Overview
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
JanOne Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.26 |
| 52 Week High | US$4.70 |
| 52 Week Low | US$0.24 |
| Beta | 2.18 |
| 1 Month Change | 39.32% |
| 3 Month Change | 530.56% |
| 1 Year Change | 280.84% |
| 3 Year Change | -51.34% |
| 5 Year Change | -18.28% |
| Change since IPO | -87.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5AR1 | DE Commercial Services | DE Market | |
|---|---|---|---|
| 7D | -23.1% | -4.6% | -1.2% |
| 1Y | 280.8% | -11.7% | 1.8% |
Return vs Industry: 5AR1 exceeded the German Commercial Services industry which returned -11.7% over the past year.
Return vs Market: 5AR1 exceeded the German Market which returned 1.8% over the past year.
Price Volatility
| 5AR1 volatility | |
|---|---|
| 5AR1 Average Weekly Movement | 36.9% |
| Commercial Services Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5AR1's share price has been volatile over the past 3 months.
Volatility Over Time: 5AR1's weekly volatility has increased from 24% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5 | Tony Isaac | www.janone.com |
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. Its lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019.
JanOne Inc. Fundamentals Summary
| 5AR1 fundamental statistics | |
|---|---|
| Market cap | €28.44m |
| Earnings (TTM) | -€15.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs 5AR1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5AR1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.10m |
| Earnings | -US$17.09m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.3% |
How did 5AR1 perform over the long term?
See historical performance and comparison